LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
View original at finance.yahoo.comLLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? Eli Lilly and Company’s LLY stock has risen 28% in the past three months…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Despite NVO having the lead in the oral obesity market, Lilly may be able to close the gap fast once orforglipron is approved by the FDA in 2026
80% confidenceEli Lilly expects new drugs (Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla), along with expanded use of existing drugs, to drive sales growth in 2026
80% confidenceNovo Nordisk expects to launch the Wegovy pill in early January 2026
80% confidenceEli Lilly expects data readouts from three phase III studies on retatrutide for treating obesity in the second half of 2026
80% confidenceMounjaro and Zepbound account for more than 50% of the company's total revenues
80% confidenceNovo Nordisk will advance next-generation obesity candidate amycretin into late-stage development, both as injection and oral pill, with phase III program planned to initiate during first quarter of 2026
80% confidenceEli Lilly is a Zacks Rank #1 (Strong Buy) stock
80% confidenceMounjaro and Zepbound are expected to continue to see strong demand in 2026
80% confidenceEli Lilly plans to file regulatory applications for orforglipron in type II diabetes in the first half of 2026
80% confidenceEli Lilly is a great stock to have in one's portfolio, given its significant price appreciation, product and pipeline portfolio, robust growth prospects and bullish analyst sentiment
80% confidenceThe obesity market is huge and multiple players can co-exist
80% confidenceStructure Therapeutics expects to initiate late-stage program of aleniglipron in obesity around mid-2026
80% confidence